Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Cevec.

    Client Virtual Booth

    CEVEC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Cevec
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Gottfried-Hagen-Str. 60 – 62 51105 Köln
    Telephone
    Telephone
    +49 (0)221 46 02 08 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cevec.com/
    Linkedin
    Linkedin
    https://de.linkedin.com/company/cevec-pharmaceuticals-gmbh
    Twitter
    Twitter
    https://twitter.com/CEVEC1

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Rokote Laboratories Licenses Cevec’s Cap® Ad Technology For Vaccine Manufacturing

    Details:

    Under the agreement, CEVEC has granted ROKOTE a non-exclusive rights to use the CAP® Ad platform for the manufacturing of adeno-based vaccines (FINCoVac 2.1) for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections.


    Lead Product(s): FINCoVac 2.1

    Therapeutic Area: Infections and Infectious Diseases Product Name: FINCoVac 2.1

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Rokote Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cevec and Carisma Therapeutics Sign License Agreement for the Use of Cap® Technology in Anti-Tumor Cell Therapies

    Details:

    CARISMA receives full rights to use the C144-LS for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications.


    Lead Product(s): RCA-free adenoviral vector,CAR-macrophage immunotherapies

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Carisma Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 02, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cevec Announces New License Agreement for Its Aav Manufacturing Technology Elevecta® IN Gene Therapy

    Details:

    Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.


    Lead Product(s): AAV-based gene therapy

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Biogen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 08, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cevec and Rznomics Sign License Agreement for THE Use of CAP® Technology inManufacturing of Adenoviral Vectors

    Details:

    Under the terms of the agreement, Rznomics will use CEVEC’s cell line technology in combination with Rznomics’ proprietary trans-splicing ribozyme technology for manufacturing of gene therapies targeting various cancer indications.


    Lead Product(s): RCA-free adenoviral vectors

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Rznomics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 20, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search